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Original Article
Left and right ventricular myocardial deformation and late 
gadolinium enhancement: incremental prognostic value in amyloid 
light-chain amyloidosis
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Background: Previous cardiac magnetic resonance (CMR) studies have shown that both late gadolinium 
enhancement (LGE) and left ventricular (LV) strain have prognostic value in amyloid light-chain (AL) 
amyloidosis, but the right ventricular (RV) strain has not yet been studied. We aim to determine the 
incremental prognostic value of LV and RV LGE and strain in AL amyloidosis.
Methods: This prospective study recruited 87 patients (age, 56.9±9.1 years; M/F, 56/31) and 20 healthy 
subjects (age, 52.7±8.1 years; M/F, 11/9) who underwent CMR. The LV LGE was classified into no, patchy 
and global groups. The RV LGE was classified into negative and positive groups. Myocardial deformation 
was measured using a dedicated software. Follow-up was performed for all-cause mortality using Cox 
proportional hazards regression and Kaplan-Meier curves.
Results: During a median follow-up of 21 months, 34 deaths occurred. Presence of LV LGE [HR 2.44, 
95% confidence interval (CI), 1.10–5.45, P=0.029] and global longitudinal strain (GLS) (HR 1.13 per 1% 
absolute decrease, 95% CI, 1.02–1.25, P=0.025) were independent LV predictors. RV LGE (HR 4.07, 95% 
CI, 1.09–15.24, P=0.037) and GLS (HR 1.10 per 1% absolute decrease, 95% CI, 1.00–1.21, P=0.047) were 
independent RV predictors. Complementary to LV LGE, LV GLS impairment or RV LGE further reduced 
survival (both log rank P<0.001).
Conclusions: This study confirms the incremental prognostic value of LV GLS and RV LGE in AL 
amyloidosis, which refines the conventional risk evaluation based on LV LGE. GLS based on non-contrast-
enhanced CMR are promising new predictors.
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Introduction 
Immunoglobulin amyloid light-chain amyloidosis (AL 
amyloidosis) is characterized as plasma cell dyscrasia with 
insoluble immunoglobulin light chain fibrils deposition 
in various organs and tissues (1). Cardiac involvement is 
likely underdiagnosed and often misdiagnosed (2,3), while 
it contributes to approximately one half of early death (4). 
Therefore, early recognition and close follow-up is of vital 
importance.
Cardiac magnetic resonance imaging (CMR) offers 
advantage of precise, comprehensive cardiac structure 
and function evaluation as well as myocardial tissue 
characterization. AL amyloidosis typically manifests as 
increased wall thickness with extensive, predominantly 
subendocardial late gadolinium enhancement (LGE), not 
limited to the left ventricle but usually including the right 
ventricle (5,6). Left ventricular (LV) LGE is proven to be 
of high diagnostic and prognostic value (7-9). Fewer studies 
focused on right ventricular (RV) LGE, with inconsistent 
prognostic results (10,11).
Recently, feature tracking CMR has emerged as a 
feasible tool for myocardial deformation analysis (12). 
Cine image-based LV strain is an independent predictor 
for mortality in AL amyloidosis, even adjusted for LV 
LGE and ejection fraction (EF) (13,14). The prognostic 
value of RV longitudinal strain has been demonstrated 
by echocardiography (15). Since CMR is the reference 
standard of RV structure and function evaluation, RV 
strain analyzed by CMR is promising in AL amyloidosis, 
but has not been reported yet. This study aims to prove 
the incremental prognostic value of LV and RV myocardial 
deformation as well as LGE in AL amyloidosis.
Methods
This research was approved by the Institutional Ethnics 
Committee for Human Research at Peking Union Medical 
College Hospital (Beijing, China). All subjects have 
consented to participate in this study.
Study subjects
This prospective study included AL amyloidosis patients 
who underwent clinical ordered CMR imaging at Peking 
Union Medical College Hospital between August 1, 2014 
and December 31, 2016. Patients with contraindications 
either to CMR imaging (i.e., CMR-incompatible devices) or 
contrast administration (i.e., estimated glomerular filtration 
rate <30 mL/min/1.73 m2) were excluded (16). Patients 
who had already received chemotherapy before CMR 
imaging were also excluded. Eighty-seven patients (age, 
56.9±9.1 years; M/F, 56/31) were consecutively recruited. 
All patients had biopsy evidence of AL amyloidosis based 
on positive Congo red stain and light chain deposition 
confirmed by immunohistochemistry, immunofluorescence 
or mass spectrometer, and 21 had histological evidence of 
myocardial involvement. All patients underwent laboratory 
examinations at baseline; serum cardiac biomarkers 
were used to categorize patients after the revised Mayo 
staging system (17). Twenty subjects (age, 52.7±8.1 years; 
M/F, 11/9) who had neither history nor symptoms of 
cardiovascular diseases were also included as healthy 
controls. 
CMR scanning protocol
CMR was performed on a 3.0 T whole-body MR system 
(MAGNETOM Skyra, Siemens Healthineers, Erlangen, 
Germany). An 18-element body matrix coil  and a 
32-element spine array coil were used for data acquisition. 
The cine images were acquired with an electrocardiogram-
gated 2D balanced steady-state free precession sequence 
during multiple breath holds. 2-, 3-, and 4-chamber long-
axis and 9–11 short-axis slices covering the LV were 
acquired. Key parameters were as follows: repetition time 
(TR)/echo time (TE), 3.3/1.43 ms; flip angle (FA), 55°–70°; 
voxel size, 1.6×1.6×6.0 mm3; temporal resolution, 45.6 ms; 
bandwidth, 962 Hz/pixel. LGE images were acquired with a 
2D phase-sensitive inversion-recovery (PSIR) gradient-echo 
pulse sequence 10 minutes after intravenous Gadolinium 
injection (16). The same long-axis and short-axis slice 
positions as for cine images were acquired. Segmented 
approach was applied for all patients, and a motion 
correction single-shot approach was applied in patients 
with arrhythmia or poor breath-holding. Parameters of the 
sequence were as follows: TR/TE/FA, 5.2 ms/1.96 ms/20°; 
voxel size, 1.4×1.4×8.0 mm3.
CMR image analysis
CMR images were independently analyzed by two 
experienced radiologists (3 and 5 years of experience in 
CMR, respectively). The LV LGE pattern was classified 
into three categories according to Boynton et al. (8) and 
Fontana et al. (9): no LGE, when there were no areas of 
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LGE; patchy LGE, when there were discrete areas of 
LGE, or there were diffuse areas of LGE in less than half 
of the short axis images; global LGE, when there was 
diffuse, transmural LGE in more than half of the short axis 
images. The RV LGE pattern was classified into negative 
and positive. RV LGE imaging was interpreted from the 
standard acquisition for LV LGE. Isolated RV free wall 
signal was considered positive. To exclude artifact, LGE 
was deemed present only if visible in two orthogonal views. 
Discrepancies were resolved in consensus during a joint 
evaluation with a third radiologist (14 years of experience). 
Cardiac structure, function and myocardial deformation 
were measured semi-automatically using dedicated 
CMR software (cvi42, version 5.3, Circle Cardiovascular 
Imaging, Calgary, Canada), initiated by the automated 
contour algorithm, then checked and revised manually. 
Standard parameters of cardiac structure (i.e., ventricular 
volumes and mass with indexing for body surface area, and 
atrial volumes) and EF were measured by contouring the 
endocardial, epicardial and atrial borders on long-axis and 
short axis cine images at end-systolic and end-diastolic 
phase (18). Myocardial deformation in longitudinal, radial 
and circumferential directions were measured by contouring 
the endocardial and epicardial borders on 2-, 3- and 
4-chamber long axis and short axis cine images at the end-
diastolic phase. The interventricular septum was considered 
part of the LV, and the RV trabeculations were regarded as 
part of the RV cavity volume. In patients without significant 
RV hypertrophy, endocardial and epicardial borders were 
defined to allow appropriate tracking points within the 
myocardial region.
Clinical follow-up
A physician blinded to the results of CMR imaging 
conducted the telephone and clinical follow-up each month. 
Unless the outcome was death from any cause, patients were 
censored at the end of the study follow-up time. If patients 
were lost to follow-up, their last clinic visit record date was 
used. 
Statistical analysis
Statistical analysis was performed using SPSS Statistics 
(version 21.0, International Business Machines, Inc., 
Armonk, New York, USA). The agreement in myocardial 
deformation parameters between two observers was 
assessed in 20 randomly selected patients using the 
intraclass correlation coefficient and Bland-Altman analyses. 
Correlation between continuous variables or categorical 
variables was assessed using the Pearson’s r correlation or 
Spearman ρ correlation, respectively. Comparison between 
patient groups and the control group was performed by 
one-way analysis of variance (ANOVA) with post-hoc 
Bonferroni correction. Statistical significance was defined 
as P<0.05. Survival was evaluated with Cox proportional 
hazards regression analysis, providing estimated hazard 
ratios (HR) with 95% confidence intervals (CI) and Kaplan-




Table 1 summarizes the characteristics of AL amyloidosis 
patients and healthy controls at baseline. Patients 
had lower LVEF and RVEF, as well as higher indexed 
LV mass and indexed RV mass, compared to healthy 
controls. Patients showed impaired LV global radial 
strain (GRS) (41.0%±16.0% vs. 60.1%±11.1%, P<0.001), 
global circumferential strain (GCS) (−19.2%±5.1% vs. 
−25.5%±2.2%, P<0.001) and global longitudinal strain 
(GLS) (−12.4%±5.7% vs. −21.1%±2.4%, P<0.001), as 
well as RV GRS (22.4%±7.1% vs. 26.9%±7.2%, P=0.011), 
GCS (−13.3%±4.4% vs. −16.0%±2.7%, P=0.004) and GLS 
(−19.1%±6.3% vs. −27.9%±2.3%, P<0.001), compared to 
healthy controls. The intra-observer and inter-observer 
variability for myocardial deformation parameters are 
shown in Table 2. The Kappa coefficient of classification 
between the two radiologists was 0.834 for LV LGE, and 
0.857 for RV LGE.
Association between LGE and strain values of LV and RV
Representative examples of LGE images and LV strain 
values from a healthy subject and AL amyloid patients with 
increasing disease burden are shown in Figure 1. LV LGE 
and RV LGE correlated significantly (ρ=0.872, P<0.001). 
The LV strain values in subgroups with different LV 
LGE patterns are shown in Figure 2. LV GRS (ρ=−0.745, 
P<0.001), LV GCS (ρ=0.743, P<0.001) and LV GLS 
(ρ=0.805, P<0.001) correlated significantly with LV LGE 
severity. Patients without LV LGE already had impaired LV 
GLS (−18.5%±2.8% vs. −21.1%±2.4%, P=0.045), compared 
to healthy controls. 
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Table 1 Baseline characteristics of the AL amyloidosis patients and healthy controls
Characteristics Patients (n=87) Healthy controls (n=20) P
Clinical
Male/female 56/31 11/9 0.452
Age (years) 56.9±9.1 52.7±8.1 0.050
NYHA (I/II/III/IV) 37/25/21/4 – –
cTnI (µg/L) 0.047 (0.014–0.127) – –
NT-proBNP (pg/mL) 2,094 [309–4,558] – –
dFLC (mg/L) 134.4 (60.0–321.3) – –
Mayo Stage (I/II/III/IV) 27/18/25/17 – –
Creatinine (µmol/L) 87.2±35.2 – –
HTN/CHD/DM/Af 16/7/3/3 – –
CMR
Indexed LVEDV (mL/m2) 77.4±15.3 76.1±8.1 0.601
Indexed LVESV (mL/m2) 32.6±12.4 22.7±4.1 <0.001**
LVEF (%) 58.4±10.7 70.2±4.3 <0.001**
LA volume (mL) 58.2±27.0 54.1±13.3 0.864
Indexed LV mass (g/m2) 54.4±19.4 38.1±6.6 <0.001**
LV LGE (none/patchy/extensive) 25/22/40 – –
LV GRS (%) 41.0±16.0 60.1±11.1 <0.001**
LV GCS (%) −19.2±5.1 −25.5±2.2 <0.001**
LV GLS (%) −12.4±5.7 −21.1±2.4 <0.001**
Indexed RVEDV (mL/m2) 63.3±14.5 71.4±9.6 0.005**
Indexed RVESV (mL/m2) 27.4±11.3 26.2±4.0 0.968
RVEF (%) 57.2±10.2 63.4±2.5 0.012*
RA volume (mL) 58.6±20.1 58.6±15.6 0.968
Indexed RV mass (g/m2) 14.0±5.7 10.8±2.1 0.034*
RV LGE (−/+) 39/48 – –
RV GRS (%) 22.4±7.1 26.9±7.2 0.011*
RV GCS (%) −13.3±4.4 −16.0±2.7 0.004**
RV GLS (%) −19.1±6.3 −27.9±2.3 <0.001**
All continuous variables are presented as mean ± SD, except for cTnI, NT-proBNP and dFLC, which are presented as medians (quartiles 
1–quartiles 3). *, P<0.05; **, P<0.01. cTnI, cardiac Troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; dFLC, serum 
immunoglobulin free light chain difference; NYHA, New York Heart Association; HTN, hypertension; CHD, coronary artery heart disease; 
DM, diabetes mellitus; Af, atrial fibrillation; CMR, cardiac magnetic resonance; LV, left ventricle; RV, right ventricle; EDV, end-diastolic 
volume; ESV, end-systolic volume; EF, ejection fraction; LGE, late gadolinium enhancement; LA, left atrium; RA, right atrium; GRS, global 
radial strain; GCS, global circumferential strain; GLS, global longitudinal strain.
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Table 2 Intra-observer and inter-observer intraclass correlation coefficient of ventricular strain
LV GRS LV GCS LV GLS RV GRS RV GCS RV GLS
Intra- 0.986 0.993 0.974 0.957 0.908 0.933
Inter- 0.917 0.933 0.928 0.925 0.865 0.919
LV, left ventricle; RV, right ventricle; GRS, global radial strain; GCS, global circumferential strain; GLS, global longitudinal strain.
Figure 1 Representative images of LGE images and LV strain values. (A) A healthy subject with negative LGE, a GRS of 63.61%, a 
GCS of −26.60%, and a GLS of −24.86%. (B) A Mayo Stage I patient with negative LGE, a GRS of 49.35%, a GCS of −22.61% and 
a GLS of −20.23%. (C) A Mayo Stage II patient with patchy LV LGE, negative RV LGE, a GRS of 40.45%, a GCS of −18.47% and a 
GLS of −17.51%. (D) A Mayo Stage III patient with patchy LV LGE, positive RV LGE, a GRS of 36.21%, a GCS of −16.53% and a 
GLS of −15.66%. (E) A Mayo Stage IV patient with extensive LV LGE, positive RV LGE, a GRS of 15.14%, a GCS of −11.65% and a 
GLS of −9.00%. LV, left ventricular; RV, right ventricular; LGE, late gadolinium enhancement; GRS, global radial strain; GCS, global 
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The RV strain values in subgroups with different RV 
LGE patterns are shown in Figure 3. RV GRS (ρ=−0.683, 
P<0.001), RV GCS (ρ=0.619, P<0.001) and RV GLS 
(ρ=0.763, P<0.001) correlated significantly with RV LGE. 
Patients without RV LGE already had impaired RV GLS 
(−24.5%±3.8% vs. −27.9%±2.3%, P=0.005), compared to 
healthy controls.
Association between CMR parameters and clinical stage
Table 3 summarizes the correlation of CMR parameters with 
Mayo Stage. The EF and mass of LV and RV correlated 
significantly with Mayo Stage (all P<0.001). The LGE 
as well as strain parameters of LV and RV correlated 
significantly with Mayo Stage (all P<0.001). Patients with 
Mayo Stage I had impaired LV GLS (−17.0%±3.4% vs. 
−21.1%±2.4%, P=0.004) and RV GLS (−23.7%±4.6% vs. 
−27.9%±2.3%, P=0.027), compared to healthy controls. 
CMR parameters and clinical outcome
During fo l low-up,  69 (79.3%) pat ients  rece ived 
Figure 2 LV strain values with different LV LGE patterns. LV GRS, LV GCS and LV GLS correlated significantly with LV LGE (all 
P<0.001) severity. Patients without LV LGE had reduced LV GLS (−18.5%±2.8% vs. −21.1%±2.4%, P=0.045), compared to healthy 
controls. LV, left ventricular; LGE, late gadolinium enhancement; GRS, global radial strain; GCS, global circumferential strain; GLS, global 
longitudinal strain.
Figure 3 RV strain values with different RV LGE patterns. RV GRS, RV GCS and RV GLS correlated significantly with RV LGE (all 
P<0.001). Patients without RV LGE had reduced RV GLS (−24.5%±3.8% vs. −27.9%±2.3%, P=0.005), compared to healthy controls. 
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s tandardized chemotherapy with thal idomide or 
bortezomib, cyclophosphamide and dexamethasone (BCD or 
TCD), 8 (9.2%) received autologous stem cell transplantation, 
and the remainder did not receive chemotherapy because of 
the expense or other reasons. At the time of the last follow-
up moment, 53 (60.9%) patients were alive, with a survival 
probability of approximately 64.4% at median follow-up time 
(21 months); 34 (39.1%) patients were dead, with a median 
time to death of 5 month. Two patients were lost to follow-up. 
Table 4 summarizes the univariate and multivariate 
Cox proportional hazard analysis of overall survival in all 
patients. Mayo Stage, LV and RV LGE, LV and RV strain 
parameters were significantly associated with all-cause 
mortality in univariate analysis. LV and RV EF, LV and 
RV mass, and right atrial volume also were predictors. LV 
LGE and RV LGE were analyzed in separate multivariate 
Cox models because of a high correlation value (ρ=0.872). 
LV LGE (HR 2.44, 95% CI, 1.10–5.45, P=0.029) and 
LV GLS (HR 1.13 per 1% absolute decrease, 95% CI, 
1.02–1.25, P=0.025) were independent predictors in a LV 
parameters based multivariate Cox model. RV LGE (HR 
4.07, 95% CI, 1.09–15.24, P=0.037) and RV GLS (HR 1.10 
per 1% absolute decrease, 95% CI, 1.00–1.21, P=0.047) 
were independent predictors in a RV parameters based 
multivariate Cox model.
For all patients, Kaplan-Meier survival curve showed 
significant difference in survival probability categorized 
by LV (Figure 4A, 96.0%, 77.3%, and 37.3% at the 21th 
month respectively, log-rank P<0.001) or RV LGE pattern 
(Figure 4B, 92.3% and 41.3% at the 21th month respectively, 
log-rank P<0.001). All patients without LV LGE had 
negative RV LGE; 14/8 patients with patchy LGE had 
negative/positive RV LGE; all patients with extensive LV 
LGE had positive RV LGE. Kaplan-Meier survival curve 
showed RV LGE further reduced survival (Figure 4C, 
96.0%, 85.7%, 62.5%, and 37.3% at the 21th month 
respectively, log-rank P<0.001). 
We assigned a score of 1 for patchy LV LGE, 2 for 
extensive LV LGE, and 1 for LV GLS ≥−11.85%, adding 
together divided patients into four groups with LV Score 
of 0, 1, 2, and 3, respectively. Kaplan-Meier survival 
curve showed significant difference in survival probability 
categorized by LV Score (Figure 5, 100.0%, 75.0%, 
73.7%, and 34.9% at the 21th month respectively, log-rank 
P<0.001). Scores based on RV LGE and GLS did not have 
statistical significance. 
Table 3 CMR parameters correlation with clinical stage in AL amyloidosis patients 
Variable Control (n=20)
Mayo Stage Correlation
I (n=27) II (n=18) III (n=25) IV (n=17) ρ P
LVEF (%) 70.2±4.3 67.0±5.9 59.1±8.4 56.3±10.2 47.2±8.3 −0.649 <0.001
Indexed LV mass (g/m2) 38.1±6.6 45.1±16.5 50.1±20.8 64.2±19.5 61.0±14.0 0.430 <0.001
LV LGE (no/patchy/
extensive)
– 18/8/1 7/5/6 0/7/18 0/2/15 0.726 <0.001
LV GRS (%) 60.1±11.1 54.1±12.6 43.3±14.4 35.0±13.7 26.5±6.2 −0.667 <0.001
LV GCS (%) −25.5±2.2 −23.5±3.2 −20.4±4.2 −17.0±4.8 −14.3±2.6 0.686 <0.001
LV GLS (%) −21.1±2.4 −17.0±3.4* −14.8±5.2 −9.2±3.6 −7.0±3.7 0.707 <0.001
RVEF (%) 63.4±2.5 63.8±6.7 60.0±10.6 55.3±8.5 46.5±6.7 −0.607 <0.001
Indexed RV mass (g/m2) 10.8±2.1 10.7±3.0 12.9±5.4 16.5±7.0 16.8±4.1 0.489 <0.001
RV LGE (−/+) – 23/4 10/8 6/19 0/17 0.650 <0.001
RV GRS (%) 26.9±7.2 26.3±6.4 23.7±6.6 21.5±7.0 16.0±4.0 −0.555 <0.001
RV GCS (%) −16.0±2.7 −14.4±6.2 −14.6±3.0 −13.1±2.9 −10.5±2.2 0.500 <0.001
RV GLS (%) −27.9±2.3 −23.7±4.6** −21.4±5.5 −16.3±5.9 −13.5±3.1 0.638 <0.001
Compared with the control, *, P=0.004; **, P=0.027. Correlation was assessed using Spearman ρ correlation. LV, left ventricle; RV, right 
ventricle; EF, ejection fraction; LGE, late gadolinium enhancement; GRS, global radial strain; GCS, global circumferential strain; GLS, 
global longitudinal strain.
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Table 4 Univariable and multivariable Cox proportional hazard analysis in AL amyloidosis patients
Variable 
Univariable Multivariable Multivariable
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Mayo Stage 1.81 (1.31–2.51) <0.001 – – – –
LVEF, per unit increase 0.94 (0.91–0.97) <0.001 – –
Indexed LV mass, per unit increase 1.03 (1.01–1.04) 0.001 – –
LV LGE 4.25 (2.22–8.14) <0.001 2.44 (1.10–5.45) 0.029
LV GRS, per unit increase 0.93 (0.91–0.96) <0.001 – –
LV GCS, per absolute unit decrease 1.18 (1.10–1.27) <0.001 – –
LV GLS, per absolute unit decrease 1.22 (1.13–1.31) <0.001 1.13 (1.02–1.25) 0.025
RVEF, per unit increase 0.96 (0.93–0.99) 0.005 – –
RA volume, per unit increase 1.02 (1.00–1.04) 0.019 – –
Indexed RV mass, per unit increase 1.08 (1.03–1.13) 0.002 – –
RV LGE 9.25 (3.24–26.43) <0.001 4.07 (1.09–15.24) 0.037
RV GRS, per unit increase 0.95 (0.90–1.00) 0.048 – –
RV GLS, per absolute unit decrease 1.18 (1.10–1.26) <0.001 1.10 (1.00–1.21) 0.047
All statistically significant prognostic factors in univariate analysis were listed. All clinically and statistically significant variables in univariate 
analysis were put into the multivariable Cox model. LV LGE and RV LGE were put in separate models because of a correlation ρ=0.872. LV, 
left ventricle; RV, right ventricle; EF, ejection fraction; LGE, late gadolinium enhancement; RA, right atrium; GRS, global radial strain; GCS, 
global circumferential strain; GLS, global longitudinal strain; HR, hazard ratio; CI, confidence interval.
Figure 4 Kaplan-Meier survival curves of LV and RV LGE. (A) Survival probability differed significantly categorized by LV LGE patterns 
(96.0%, 77.3%, and 37.3% at the 21th month respectively, log-rank P<0.001). (B) Survival probability differed significantly categorized 
by RV LGE patterns (92.3% and 41.3% at the 21th month respectively, log-rank P<0.001). (C) Survival probability differed significantly 
categorized by LV and RV LGE patterns (96.0%, 85.7%, 62.5%, and 37.3% at the 21th month respectively, log-rank P<0.001). LV, left 
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Discussion
Our study has a series of important findings. First, LV and 
RV strain values correlated significantly with clinical and 
other imaging parameters of AL amyloidosis disease burden. 
Second, in patients without serum cardiac biomarkers or 
LGE evidence of cardiac involvement, LV and RV GLS was 
already impaired. Third and most importantly, LV and RV 
LGE and GLS were independent predictors for all-cause 
mortality in AL amyloidosis. Complementary to LV LGE, 
LV GLS impairment or RV LGE further reduced survival.
LGE CMR is a classic imaging tool to diagnose cardiac 
amyloidosis. However, the recognition of LGE lesions 
involves delineation of abnormal tissue from normal 
tissue, thus early identification of mild cases or diffuse 
cardiomyopathy can easily be missed. On the other hand, 
kidney involvement is common in AL amyloid (19,20), 
and approximately 15% of patients were excluded in 
this study because of renal function impairment. Efforts 
have been made to search for non-contrast-enhanced 
quantitative parameters, yielding a series of cardiac 
structural and functional predictors derived from CMR 
and echocardiography (6,10). Feature tracking CMR based 
myocardial deformation analysis has attracted increasing 
attention, as it yields tri-directional strain values from 
cine-images without additional sequence scanning or 
contrast injection (12,21). Consistent with previous studies 
(14,22,23), we proved that LV strain values correlated 
significantly with clinical and other imaging parameters of 
AL amyloidosis disease burden, and GLS showed earlier 
impairment than serum biomarkers, EF or LGE. We and 
others (13,14) demonstrated that LV strain values are 
independently prognostic of mortality. The difference was 
that we and Illman et al. (13) found that LV GLS is the 
independent predictor, while Wan et al. (14) found that LV 
GCS independently predicted mortality. The difference 
in most predictive strain parameter might due to different 
vendors or software used and different parameters included.
Another novelty of this study is the evidence of RV 
parameters for mortality prediction in AL amyloidosis. We 
demonstrated that RV GLS is an independent predictor, 
which to our knowledge has not been reported before. 
Cardiac involvement typically manifests as extensive LGE 
not limited to the LV but also in the RV (5,24). We validated 
the prognostic value of LV LGE, consistent with previous 
important studies (7-9). Fewer data are available regarding 
the value of RV LGE in AL amyloidosis, which is more 
difficult to be identified and categorized due to the relatively 
thin ventricular wall and abundant epicardial fat. Wan et al. 
demonstrated that RV LGE is an independent predictor 
of mortality (11), while Bodez et al. pointed out that plane 
systolic excursion (TAPSE) derived by echocardiography 
rather than RV LGE is independently prognostic (10). 
We proved that RV LGE is an independent predictor over 
Mayo Stage, RVEF, RV mass and RA volume. Besides, for 
patients with the same LV LGE pattern, survival probability 
also differed significantly according to RV LGE pattern. 
Possible explanations for the difference among studies are 
different amyloidosis subtypes investigated and different 
imaging parameters included in the survival analysis.
This study has some limitations. The main limitation 
is that this is a single-center study. Although we recruited 
a relatively large patient population and provided good 
reproducibility of strain values, the results need to be 
confirmed in other centers with different vendors and 
analysis methods. Second, we did not perform mortality 
analysis of cardiovascular events, because many patients, 
although they got a treatment plan in our hospital, received 
treatment at their home institution, for whom detailed data 
of mortality cause is incomplete. Third, we found strain 
impairment in patients without LGE, but few patients 
underwent myocardial biopsy. A lack of pathology evidence 
for cardiac involvement is common with most studies.
Conclusions
This study confirms that strain values based on non-
contrast-enhanced CMR are promising early diagnostic 
Figure 5 Kaplan-Meier survival curve of LV Score. Patients 
were divided into four groups with LV Score of 0, 1, 2, and 3, 
respectively, with 1 for patchy LV LGE, 2 for extensive LV LGE, 
and 1 for LV GLS ≥−11.85% (median value). Patients categorized 
by LV Score differed significantly in survival probability (100.0%, 
75.0%, 73.7%, and 34.9% at the 21th month respectively, log-rank 
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parameters and new predictors for AL amyloidosis, in 
particular longitudinal strain. Besides, this study highlighted 
the prognostic value of RV LGE and RV strain values, 
which refined the conventional risk evaluation based on LV 
impairment.
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